| Pharmaceutical policy reforms to regulate drug prices in the Asia Pacific region: the case of Australia, China, India, Malaysia, New Zealand, and South Korea SS Hasan, CS Kow, D Dawoud, O Mohamed, D Baines Value in health regional issues 18, 18-23, 2019 | 35 | 2019 |
| Clinical and economic burden of nonalcoholic steatohepatitis in Saudi Arabia, United Arab Emirates and Kuwait FM Sanai, A Al Khathlan, A Al Fadhli, AS Jazzar, AM Hashim, E Mansour, ... Hepatology international 15, 912-921, 2021 | 20 | 2021 |
| The impact of a pricing policy change on retail prices of medicines in Egypt O Mohamed, DH Kreling Value in Health Regional Issues 10, 14-18, 2016 | 12 | 2016 |
| Translation, cultural adaptation and psychometric validation of the SF-6D measure of health-related quality of life for use in Arabic-Speaking countries DM Dawoud, F El-Dahiyat, A Abojedi, N Dawoud, AM Soliman, M Hussein, ... Research in Social and Administrative Pharmacy 16 (12), 1754-1759, 2020 | 8 | 2020 |
| Economic evaluation of Cladribine tablets in patients with high disease activity–relapsing-remitting multiple sclerosis in the Kingdom of Saudi Arabia S Bohlega, A Elboghdady, A Al-Johani, K Mahajan, MK Mughari, ... Value in Health Regional Issues 25, 189-195, 2021 | 6 | 2021 |
| Economic evaluation of cladribine tablets in high disease activity (HDA) relapsing multiple sclerosis (RMS) patients in Lebanon M Matni, B Yamout, S Koussa, C Khamis, L Fleifel, S Sharifi, O Mohamed Multiple Sclerosis and Related Disorders 67, 104169, 2022 | 4 | 2022 |
| The impact of direct price controls on pharmaceutical prices in Egypt OE Mohamed The University of Wisconsin-Madison, 2014 | 4 | 2014 |
| Budget impact analysis of cladribine tablets in relapsing-remitting multiple sclerosis (RRMS) patients in Kingdom of Saudi Arabia SA Bohlega, H Al-Mudaiheem, M Alhowimel, K Mahajan, O Mohamed, ... Multiple Sclerosis and Related Disorders 37, 2020 | 3 | 2020 |
| PND53 economic evaluation of cladribine tablets in relapsing multiple sclerosis (RMS) patients with high disease activity (HDA) in Lebanon M Metni, B Yamout, S Koussa, C Khamis, L Fleifel, S Sharifi, O Mohamed Value in Health 22, S746, 2019 | 2 | 2019 |
| PBI4 budget impact analysis of golimumab in adult rheumatoid arthritis patients in Kingdom of Saudi Arabia A Al Jedai, H AL-Mudaiheem, P Pathak, N Awad, O Mohamed, ... Value in Health 22, S47, 2019 | 2 | 2019 |
| Translation and cultural adaptation of the SF-6D questionnaire for use in Arabic-Speaking countries DM Dawoud, AM Soliman, L Alhyas, MEK Amin, M Hussein, O Mohamed Value in Health 16 (7), A606, 2013 | 2 | 2013 |
| A cost-comparative analysis of intravenous ferric Carboxymaltose versus iron sucrose for the ambulatory treatment of iron-deficiency anemia in a major tertiary care hospital in … S Alzahrani, M Almeziny, A Narang, O Mohamed, S Almeziny, A Almeziny International Journal of Clinical Medical Research 1 (1), 28-35, 2023 | 1 | 2023 |
| PBI15 The economic burden for the management of moderate-to-severe psoriasis in the Kingdom of Saudi Arabia H Al-Omar, E Altawil, IR Hamadah, M Alsaqa'aby, MA Al Shahwan, ... Value in Health 23, S413, 2020 | 1 | 2020 |
| PCV17 budget impact analysis of proprotein convertase Subtilisin/Kexin type 9 inhibitors (PCSK9I) use in combination with statins for treatment of uncontrolled low-density … A Al Jedai, H Al-Mudaiheem, A Al-Zoby, AB Hamada, M Sobhy, P Pathak, ... Value in Health 23, S92-S93, 2020 | 1 | 2020 |
| PMS23-optimizing treatment for rheumatoid arthritis in the kingdom of Saudi Arabia (OPTRA) HY Almudaiheem, O Mohamed, D Dawoud, Y Alsuwayeh, K Alenzi, ... Value in Health 21, S291, 2018 | 1 | 2018 |
| Characteristics of Products with Price changes after a policy change in Egypt O Mohamed, D Kreling Value in Health 18 (3), A76, 2015 | 1 | 2015 |
| Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia H Al-Abdulkarim, Y Sharma, SM Attar, W Husain, I Al-Homood, B Al Omari, ... Journal of Medical Economics 27 (1), 134-144, 2024 | | 2024 |
| Novel methods and technologies for the evaluation of drug outcomes and policies B Adamson, A Makady, G Sarri, O Mohamed, Z Babar, DM Dawoud Frontiers in Pharmacology 15, 1396034, 2024 | | 2024 |
| OPEN ACCESS EDITED AND REVIEWED BY MT Silva, B Adamson, B Adamson, A Makady, G Sarri, O Mohamed, ... Novel methods and technologies for the evaluation of drug outcomes and …, 2024 | | 2024 |
| EE727 The Budgetary Impact of Introducing Expanded Haemodialysis, Enabled by Theranova (HDX), Compared to High-Flux Haemodialysis (HF-HD) in Private Sector in the Kingdom of … O Mohamed, F Shaheen, M Safwat, K Abouzaid, M Alsaqaaby, ... Value in Health 26 (12), S194, 2023 | | 2023 |
